Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Corvus Pharmaceuticals reports Q3 EPS (32c), consensus (16c) » 16:10
11/03/22
11/03
16:10
11/03/22
16:10
CRVS

Corvus Pharmaceuticals

/

+

As of September 30 Corvus…

As of September 30 Corvus had cash, cash equivalents and marketable securities totaling $49.6 million. This compared to cash, cash equivalents and marketable securities of $69.5 million as of December 31, 2021. Consistent with last quarter, Corvus expects full year 2022 net cash used in operating activities to be between $27 million and $29 million, resulting in a projected cash balance of between $40.5 million and $42.5 million as of December 31, 2022. Based on its current plans, Corvus expects its cash to fund operations into early 2024.

ShowHide Related Items >><<
CRVS Corvus Pharmaceuticals
/

+

CRVS Corvus Pharmaceuticals
/

+

10/07/22 Ladenburg
Corvus Pharmaceuticals initiated with a Buy at Ladenburg
08/09/22 Cantor Fitzgerald
Corvus Pharmaceuticals price target lowered to $4 from $8 at Cantor Fitzgerald
12/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target raised to $8 from $5 at Cantor Fitzgerald
12/01/21 Jefferies
Corvus Pharmaceuticals initiated with a Buy at Jefferies
CRVS Corvus Pharmaceuticals
/

+

Earnings
Corvus Pharmaceuticals reports Q3 EPS (32c), consensus (16c) » 16:10
11/03/22
11/03
16:10
11/03/22
16:10
CRVS

Corvus Pharmaceuticals

/

+

As of September 30 Corvus…

As of September 30 Corvus had cash, cash equivalents and marketable securities totaling $49.6 million. This compared to cash, cash equivalents and marketable securities of $69.5 million as of December 31, 2021. Consistent with last quarter, Corvus expects full year 2022 net cash used in operating activities to be between $27 million and $29 million, resulting in a projected cash balance of between $40.5 million and $42.5 million as of December 31, 2022. Based on its current plans, Corvus expects its cash to fund operations into early 2024.

ShowHide Related Items >><<
CRVS Corvus Pharmaceuticals
/

+

CRVS Corvus Pharmaceuticals
/

+

10/07/22 Ladenburg
Corvus Pharmaceuticals initiated with a Buy at Ladenburg
08/09/22 Cantor Fitzgerald
Corvus Pharmaceuticals price target lowered to $4 from $8 at Cantor Fitzgerald
12/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target raised to $8 from $5 at Cantor Fitzgerald
12/01/21 Jefferies
Corvus Pharmaceuticals initiated with a Buy at Jefferies
CRVS Corvus Pharmaceuticals
/

+

Over a month ago
Earnings
Corvus begins ciforadenant trial to evaluate as therapy for RCC in combo » 16:27
10/25/22
10/25
16:27
10/25/22
16:27
CRVS

Corvus Pharmaceuticals

/

+

Corvus Pharmaceuticals…

Corvus Pharmaceuticals announced the initiation of a Phase 1b/2 clinical trial evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer RCC in combination with ipilimumab and nivolumab . The Phase 1b/2 study is being conducted by the Kidney Cancer Research Consortium and is led by The University of Texas MD Anderson Cancer Center, one of seven partner institutions that make up the KCRC. The study is expected to enroll up to 60 patients at KCRC partner institutions. "Ciforadenant is one of the most studied adenosine receptor antagonists and we have presented encouraging clinical data in very advanced refractory patients with renal cell cancer, demonstrating its anti-tumor activity as a monotherapy and in combination with anti-PD-L1 therapy," said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. "In addition, we published preclinical data in Cancer Immunology Research in 2018 that showed that ciforadenant combined with anti-CTLA-4 and anti-PD-1 therapy is highly active, which resulted in complete elimination of tumors, even in the setting of treatment of established tumors. Further laboratory studies have uncovered a novel mechanism of action that we believe may synergize with anti-CTLA-4 therapy. Together we believe this provides strong rationale for this Phase 1b/2 clinical trial in first line renal cell cancer and we are excited to partner with the Kidney Cancer Research Consortium, who is leading the clinical trial. And given this is an open-label study, we hope to have preliminary results relatively early in the trial."

ShowHide Related Items >><<
CRVS Corvus Pharmaceuticals
/

+

CRVS Corvus Pharmaceuticals
/

+

10/07/22 Ladenburg
Corvus Pharmaceuticals initiated with a Buy at Ladenburg
08/09/22 Cantor Fitzgerald
Corvus Pharmaceuticals price target lowered to $4 from $8 at Cantor Fitzgerald
12/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target raised to $8 from $5 at Cantor Fitzgerald
12/01/21 Jefferies
Corvus Pharmaceuticals initiated with a Buy at Jefferies
CRVS Corvus Pharmaceuticals
/

+

Initiation
Corvus Pharmaceuticals initiated with a Buy at Ladenburg » 06:59
10/07/22
10/07
06:59
10/07/22
06:59
CRVS

Corvus Pharmaceuticals

/

+

Ladenburg analyst Aydin…

Ladenburg analyst Aydin Huseynov initiated coverage of Corvus Pharmaceuticals with a Buy rating and $2 price target.

ShowHide Related Items >><<
CRVS Corvus Pharmaceuticals
/

+

CRVS Corvus Pharmaceuticals
/

+

08/09/22 Cantor Fitzgerald
Corvus Pharmaceuticals price target lowered to $4 from $8 at Cantor Fitzgerald
12/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target raised to $8 from $5 at Cantor Fitzgerald
12/01/21 Jefferies
Corvus Pharmaceuticals initiated with a Buy at Jefferies
CRVS Corvus Pharmaceuticals
/

+

Hot Stocks
Corvus announces partner receives approval for IND application in China » 16:16
09/26/22
09/26
16:16
09/26/22
16:16
CRVS

Corvus Pharmaceuticals

/

+

Corvus Pharmaceuticals…

Corvus Pharmaceuticals announced that the IND application to initiate a Phase 1/1b clinical trial of mupadolimab has been approved by the Center for Drug Evaluation of the China National Medical Products Administration. The study will be conducted by Angel Pharmaceuticals, Corvus' partner in China. Mupadolimab is a humanized monoclonal antibody designed to be directed against CD73 with a proposed unique mechanism of activating B cells to generate immune responses to tumor antigens and viruses, in patients with relapsed refractory non-small cell lung cancer, or NSCLC, and head and neck squamous cell cancers, or HNSCC. Corvus co-founded Angel Pharma to develop its pipeline in greater China. Angel Pharma licensed the rights from Corvus to develop, manufacture and commercialize mupadolimab in greater China. Corvus has studied mupadolimab in a Phase 1/1b clinical trial, with a focus on expansion cohorts in patients with HNSCC that have failed previous treatment with anti-PD-1 therapy and chemotherapy and relapsed refractory NSCLC who have failed previous treatment with anti-PD(L)-1 therapy and chemotherapy. Based on the results to-date, Corvus believes this program is ready to advance into a randomized Phase 2 clinical trial evaluating mupadolimab in combination with pembrolizumab and chemotherapy as a potential front-line therapy for the treatment of patients with NSCLC. Angel Pharma is examining mupadolimab in a Phase 1/1b clinical trial designed to confirm the dose and evaluate the safety, pharmacokinetics, immune biomarkers, and efficacy as a single agent, and in combination with pembrolizumab. Patients with NSCLC and HNSCC are eligible. The clinical trial's efficacy endpoints are complete response, partial response, disease control rate, duration of response, progression-free survival, and overall survival.

ShowHide Related Items >><<
CRVS Corvus Pharmaceuticals
/

+

CRVS Corvus Pharmaceuticals
/

+

08/09/22 Cantor Fitzgerald
Corvus Pharmaceuticals price target lowered to $4 from $8 at Cantor Fitzgerald
12/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target raised to $8 from $5 at Cantor Fitzgerald
12/01/21 Jefferies
Corvus Pharmaceuticals initiated with a Buy at Jefferies
CRVS Corvus Pharmaceuticals
/

+

Over a quarter ago
Recommendations
Corvus Pharmaceuticals price target lowered to $4 from $8 at Cantor Fitzgerald » 08:11
08/09/22
08/09
08:11
08/09/22
08:11
CRVS

Corvus Pharmaceuticals

/

+

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Li Watsek lowered the firm's price target on Corvus Pharmaceuticals to $4 from $8 and keeps an Overweight rating on the shares. Corvus Pharmaceuticals reported Q2 financial results and gave a business update, including that the pause of the Phase 2 trial initiation of mupadolimab in 1L non-small cell lung cancer, and the prioritization of CPI-818, an ITK-inhibitor in T-cell lymphoma and autoimmune diseases, driven by early encouraging clinical activities, Watsek tells investors in a research note. While sentiment around the stock has been low, Watsek thinks this could change on near-term CPI-818 data to be presented in December at the annual American Society of Hematology meeting.

ShowHide Related Items >><<
CRVS Corvus Pharmaceuticals
/

+

CRVS Corvus Pharmaceuticals
/

+

12/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target raised to $8 from $5 at Cantor Fitzgerald
12/01/21 Jefferies
Corvus Pharmaceuticals initiated with a Buy at Jefferies
09/22/21 Roth Capital
Corvus recent rally due to AstraZeneca data, says Roth Capital
CRVS Corvus Pharmaceuticals
/

+

Earnings
Corvus Pharmaceuticals reports Q2 EPS (18c), consensus (18c) » 16:55
08/08/22
08/08
16:55
08/08/22
16:55
CRVS

Corvus Pharmaceuticals

/

+

As of June 30, Corvus had…

As of June 30, Corvus had cash, cash equivalents and marketable securities totaling $56.7M. This compared to cash, cash equivalents and marketable securities of $69.5M as of December 31, 2021. Based on its current plans, the company expects its cash to fund operations into early 2024. "We continue to see encouraging clinical data from the Phase 1 clinical trial of CPI-818 in T cell lymphomas, both in its effects on tumor growth and its effects on normal T cells. Based on this data, along with new preclinical models that demonstrate its potential in autoimmune and allergic diseases, we have decided to focus our efforts on advancing the development of CPI-818," said Richard Miller, co-founder, president and chief executive officer of Corvus. "The intensification of efforts on this program brings other advantages - we expect that we can generate additional clinical data in the near-term, we believe CPI-818 is the most advanced program targeting ITK inhibition and our team has expertise developing and launching an analogous target in BTK inhibition with Ibrutinib."

ShowHide Related Items >><<
CRVS Corvus Pharmaceuticals
/

+

CRVS Corvus Pharmaceuticals
/

+

12/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target raised to $8 from $5 at Cantor Fitzgerald
12/01/21 Jefferies
Corvus Pharmaceuticals initiated with a Buy at Jefferies
09/22/21 Roth Capital
Corvus recent rally due to AstraZeneca data, says Roth Capital
CRVS Corvus Pharmaceuticals
/

+

Hot Stocks
Corvus Pharmaceuticals provides updates at R&D symposium » 08:00
05/10/22
05/10
08:00
05/10/22
08:00
CRVS

Corvus Pharmaceuticals

$1.12 /

-0.165 (-12.89%)

Corvus Pharmaceuticals is…

Corvus Pharmaceuticals is hosting an R&D Symposium today in New York City. During the event, which will also be available via webcast, the company plans to provide updates on its three clinical programs: mupadolimab, ciforadenant and CPI-818. The R&D Symposium will include a review of patient case studies from the ongoing Phase 1/1b clinical trial of CPI-818 in patients with relapsed T cell lymphomas, including peripheral T cell lymphoma, cutaneous T cell lymphoma, angioimmunoblastic T cell lymphoma and others. In this trial, which was designed to select the optimal dose of CPI-818, doses of 100, 200, 400 and 600 mg taken twice a day were given to successive cohorts of patients. The 200 mg dose was identified as the optimal dose, and at this dose, four of five patients are responding to therapy as follows: PTCL patient achieved a complete response lasting 12 months on CPI-818 treatment with complete remission duration extending an additional 7 months with no further therapy (total complete remission duration of 19 months); PTCL patient achieved a partial response with treatment ongoing; AITL patient that is responding on treatment; CTCL patient achieved nodal complete response with treatment lasting 21 months; In addition, a PTCL patient receiving the 600 mg dose achieved a partial response that lasted for several months; the patient went on to receive a bone marrow transplant.

ShowHide Related Items >><<
CRVS Corvus Pharmaceuticals
$1.12 /

-0.165 (-12.89%)

CRVS Corvus Pharmaceuticals
$1.12 /

-0.165 (-12.89%)

12/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target raised to $8 from $5 at Cantor Fitzgerald
12/01/21 Jefferies
Corvus Pharmaceuticals initiated with a Buy at Jefferies
09/22/21 Roth Capital
Corvus recent rally due to AstraZeneca data, says Roth Capital
08/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target lowered to $5 from $10 at Cantor Fitzgerald
CRVS Corvus Pharmaceuticals
$1.12 /

-0.165 (-12.89%)

Earnings
Corvus Pharmaceuticals reports Q4 EPS (20c), consensus (19c) » 16:43
03/10/22
03/10
16:43
03/10/22
16:43
CRVS

Corvus Pharmaceuticals

$1.59 /

-0.05 (-3.05%)

As of December 31, 2021,…

As of December 31, 2021, Corvus had cash, cash equivalents and marketable securities totaling $69.5M compared to $44.3M as of December 31, 2020. Corvus expects full year 2022 net cash used in operating activities to be between $34M and $36M. "We continue to advance three clinical programs for novel product candidates targeting CD73, the adenosine 2A receptor, and ITK, which are involved in immune response to cancers and other diseases," said Richard Miller, co-founder, president and chief executive officer of Corvus. "We have established sound scientific foundations for our product candidates, which give us confidence as we initiate mid-stage clinical trials in front-line treatment of lung cancer and renal cell cancer. In addition, our partnership with Angel Pharmaceuticals has expanded the clinical development of CPI-818 for T cell lymphomas into China and is accelerating global development of this product candidate."

ShowHide Related Items >><<
CRVS Corvus Pharmaceuticals
$1.59 /

-0.05 (-3.05%)

CRVS Corvus Pharmaceuticals
$1.59 /

-0.05 (-3.05%)

12/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target raised to $8 from $5 at Cantor Fitzgerald
12/01/21 Jefferies
Corvus Pharmaceuticals initiated with a Buy at Jefferies
09/22/21 Roth Capital
Corvus recent rally due to AstraZeneca data, says Roth Capital
08/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target lowered to $5 from $10 at Cantor Fitzgerald
CRVS Corvus Pharmaceuticals
$1.59 /

-0.05 (-3.05%)

CRVS Corvus Pharmaceuticals
$1.59 /

-0.05 (-3.05%)

Hot Stocks
Corvus Pharmaceuticals announces new preclinical data on CPI-818 » 10:32
12/13/21
12/13
10:32
12/13/21
10:32
CRVS

Corvus Pharmaceuticals

$2.94 /

+0.09 (+3.16%)

Corvus Pharmaceuticals…

Corvus Pharmaceuticals announced new preclinical data demonstrating the potential of CPI-818, the company's ITK inhibitor, for the prevention and therapy of acute graft versus host disease, aGVHD, in patients receiving allogeneic hematopoietic cell transplantation. The data will be presented today in a poster at the 63rd American Society of Hematology, ASH, Annual Meeting & Exposition. CPI-818 is an investigational, orally bioavailable, covalent inhibitor of ITK designed to have low nanomolar affinity. In vitro studies have shown that it potently inhibited T cell receptor signal transduction. Preclinical Data Presented at ASH: The study evaluated CPI-818 in two mouse models of aGVHD. Recipient mice were pre-conditioned by having their bone marrow ablated with high dose radiation, and then received an allogeneic bone marrow transplantation.The results of the study demonstrated that mice receiving CPI-818 had: Statistically significant improvement in GVHD score and survival compared to the placebo group; Increased concentrations of anti-inflammatory cytokines; Increased numbers of T suppressor cells in their spleens. Collectively, the data demonstrated that ITK inhibition with CPI-818 has potential as a targeted approach to prevent or treat aGVHD through the suppression of T cell activation and proliferation, reducing concentrations of pro-inflammatory cytokines and increasing the concentration of anti-inflammatory cytokines. Corvus is studying CPI-818 in a Phase 1/1b clinical trial that was designed to select the optimal dose of CPI-818 and evaluate its safety, pharmacokinetics, target occupancy, biomarkers and efficacy. Interim data from the Phase 1/1b clinical trial of CPI-818 for T cell lymphoma demonstrated tumor responses in very advanced, refractory, difficult to treat T cell malignancies. Corvus' partner in China, Angel Pharmaceuticals, plans to initiate a Phase 1/1b clinical trial of CPI-818 for the treatment of refractory T cell lymphomas in early 2022, with the potential to expand into autoimmune diseases over time. Angel Pharmaceuticals will be responsible for all expenses related to executing the trial in China.

ShowHide Related Items >><<
CRVS Corvus Pharmaceuticals
$2.94 /

+0.09 (+3.16%)

CRVS Corvus Pharmaceuticals
$2.94 /

+0.09 (+3.16%)

12/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target raised to $8 from $5 at Cantor Fitzgerald
12/01/21 Jefferies
Corvus Pharmaceuticals initiated with a Buy at Jefferies
09/22/21 Roth Capital
Corvus recent rally due to AstraZeneca data, says Roth Capital
08/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target lowered to $5 from $10 at Cantor Fitzgerald
CRVS Corvus Pharmaceuticals
$2.94 /

+0.09 (+3.16%)

  • 12
    Feb
CRVS Corvus Pharmaceuticals
$2.94 /

+0.09 (+3.16%)

CRVS Corvus Pharmaceuticals
$2.94 /

+0.09 (+3.16%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.